16th April 2019: There have been different ways of treating cancer, such as surgery, internal and external radiation therapies, etc. Brachytherapy also known as internal radiation, helps doctors deliver a high or low dosage of radioactive drugs to specific body parts for treating cancer cells. Product innovations, R&D initiatives, and technological advancements are fueling the popularity of the market.
HDR; An Advanced Tech for Treating Prostate Cancer
Modern society has witnessed technology in action when it comes to the healthcare industry. One in seven men are diagnosed with cancer in their lifetime and the good news is that more people are surviving owing to improving treatments. Brachytherapy has altered cancer therapy standards and is enhancing the chances of optimal patient outcomes. High-dose-rate (HDR) can deliver concentrated radiation bursts for a short amount of time. This procedure has registered better tolerance with fewer side effects. HDR has found its widespread application in treating prostate cancer and is anticipated to bode well during the upcoming years.
A Seed of Hope
The high-dose-rate techniques deliver seeds or pallets of radioactive drugs contained in an afterload device, placing it directly at the tumor site for a brief period of time. This is minimally invasive and eliminates any side effects by sparing the surrounding healthy tissues. HDR has been gaining traction over the past few years as a less harsh alternative to conventional radiation therapy. In March 2018, the Journal of the American Medical Association (JAMA) revealed that mortality rate due to prostate cancer dropped to 3 percent (versus 12 and 13 percent, when treated with external beam radiotherapy (EBRT) alone). This fact can be attributed to the gauging effectiveness of combining EBRT and brachytherapy. IsoRay introduced HDR cesium (Cs)-131 with superior real-time clinical outcomes.
Market Insights:
Internal radiation therapy has proven to be very effective in treating cancer, as it has a minimal risk of side effects. This can be owed to of its nature of targeted drug delivery an on-point treatment mechanism from inside the body. According to the World Health Organization, more than 2 million women are affected by breast cancer and the number is rising each year. Presence of a favorable regulatory scenario and several acquisition activities are playing a pivotal role in market’s further expansion. iCAD, Inc., in February 2019 announced their collaboration with the Karolinska Institutet to implement iCAD’s AI cancer detection software to assess an individual’s risk of inflicting or developing breast cancer.
The competitive landscape showcases the profiles and business strategies of the major players, along with their recent developments. The brachytherapy market is highly fragmented with a presence of several key players like GE Healthcare, IsoRay Medical, Inc., Eckert & Ziegler BEBIG, Carl Zeiss Meditec AG, Panacea Medical Technologies, Argon Medical Devices Inc., Boston Scientific Corporation, Elekta AB, CR Bard Inc., and Varian Medical Systems, Inc., among others. Growing investments in medical research are providing lucrative opportunities for industry players in North America. Asia Pacific is the fastest growing region owing to the rising number of geriatric populations, disposable income, and surging pool of medical practitioners.
No comments:
Post a Comment